Key Points
- RA Capital Management sold 3,448,811 Sionna Therapeutics shares at an average price of $6.33, generating approximately $21.8 million and reducing its position by 50%.
- Sionna’s shares opened at $6.00, near the lower end of their 52-week range of $4.01 to $54.97. The company reported a quarterly loss of $0.66 per share, slightly below analyst expectations.
- Analyst sentiment is mostly cautious, with one Buy, eleven Hold, and one Sell rating; the consensus rating is Hold, despite a reported average price target of $42.33.
Sionna Therapeutics, Inc. (NASDAQ:SION - Get Free Report) Director Ra Capital Management, L.P. sold 3,448,811 shares of the stock in a transaction dated Thursday, September 17th. The stock was sold at an average price of $6.33, for a total value of $21,830,973.63. Following the transaction, the director directly owned 3,448,812 shares in the company, valued at approximately $21,830,979.96. The trade was a 50.00% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink.
Sionna Therapeutics Price Performance
NASDAQ SION opened at $6.00 on Tuesday. The company has a market cap of $271.26 million, a P/E ratio of -2.75 and a beta of 0.89. The stock has a 50-day moving average of $21.75 and a two-hundred day moving average of $33.34. Sionna Therapeutics, Inc. has a 1-year low of $4.01 and a 1-year high of $54.97.
Sionna Therapeutics (NASDAQ:SION - Get Free Report) last issued its quarterly earnings results on Thursday, August 6th. The company reported ($0.66) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.64) by ($0.02). On average, analysts anticipate that Sionna Therapeutics, Inc. will post -2.54 EPS for the current fiscal year.
Institutional Trading of Sionna Therapeutics
Large investors have recently made changes to their positions in the company. Engineers Gate Manager LP acquired a new stake in Sionna Therapeutics in the second quarter valued at approximately $686,000. AXQ Capital LP acquired a new position in Sionna Therapeutics during the 2nd quarter worth approximately $202,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its holdings in Sionna Therapeutics by 9,056.9% during the 2nd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 10,622 shares of the company's stock worth $467,000 after acquiring an additional 10,506 shares in the last quarter. Wellington Management Group LLP purchased a new stake in shares of Sionna Therapeutics in the 2nd quarter valued at approximately $1,644,000. Finally, Artia Global Partners LP acquired a new stake in shares of Sionna Therapeutics in the 2nd quarter valued at $5,267,000.
Wall Street Analysts Forecast Growth
A number of equities research analysts have issued reports on the stock. Raymond James Financial lowered shares of Sionna Therapeutics from a "strong-buy" rating to a "market perform" rating in a report on Monday, August 10th. Citizens Jmp downgraded shares of Sionna Therapeutics from an "outperform" rating to a "market perform" rating in a research note on Monday, August 10th. Citigroup lowered Sionna Therapeutics from an "outperform" rating to a "market perform" rating in a research report on Monday, August 10th. Royal Bank Of Canada upgraded Sionna Therapeutics from an "underperform" rating to a "sector perform" rating and set a $5.00 price objective on the stock in a research note on Monday, August 10th. Finally, Weiss Ratings reiterated a "sell (d-)" rating on shares of Sionna Therapeutics in a report on Wednesday, August 5th. One analyst has rated the stock with a Buy rating, eleven have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock presently has an average rating of "Hold" and a consensus price target of $42.33.
Read Our Latest Analysis on SION
About Sionna Therapeutics
(
Get Free Report)
Sionna Therapeutics is a clinical-stage biopharmaceutical company focused on developing treatments for cystic fibrosis (CF), a genetic disease that affects the lungs and other organs. The company is developing small-molecule therapies designed to address defects in the cystic fibrosis transmembrane conductance regulator (CFTR) protein, which is responsible for transporting salt and fluids across cell membranes.
Sionna's research is centered on nucleotide-binding domain 1 (NBD1) correctors.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
